| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4761 | 2014 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3099 | 2013 |
| Detection and localization of surgically resectable cancers with a multi-analyte blood test JD Cohen, L Li, Y Wang, C Thoburn, B Afsari, L Danilova, C Douville, ... Science 359 (6378), 926-930, 2018 | 2391 | 2018 |
| Pembrolizumab in microsatellite-instability–high advanced colorectal cancer T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... New England Journal of Medicine 383 (23), 2207-2218, 2020 | 1994 | 2020 |
| Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ... The Journal of pathology 232 (2), 199-209, 2014 | 1497 | 2014 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ... Science translational medicine 8 (346), 346ra92-346ra92, 2016 | 1390 | 2016 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 957 | 2012 |
| Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ... Cancer 117 (20), 4623-4632, 2011 | 835 | 2011 |
| Effect of aspirin on all-cause mortality in the healthy elderly JJ McNeil, MR Nelson, RL Woods, JE Lockery, R Wolfe, CM Reid, ... New England Journal of Medicine 379 (16), 1519-1528, 2018 | 803 | 2018 |
| Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032, 2015 | 739 | 2015 |
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ... Annals of Oncology 26 (8), 1715-1722, 2015 | 636 | 2015 |
| Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers JD Cohen, AA Javed, C Thoburn, F Wong, J Tie, P Gibbs, CM Schmidt, ... Proceedings of the National Academy of Sciences 114 (38), 10202-10207, 2017 | 536 | 2017 |
| Effect of aspirin on disability-free survival in the healthy elderly JJ McNeil, RL Woods, MR Nelson, CM Reid, B Kirpach, R Wolfe, E Storey, ... New England Journal of Medicine 379 (16), 1499-1508, 2018 | 516 | 2018 |
| Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer J Tie, JD Cohen, Y Wang, M Christie, K Simons, M Lee, R Wong, ... JAMA oncology 5 (12), 1710-1717, 2019 | 504 | 2019 |
| Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer RN Jorissen, P Gibbs, M Christie, S Prakash, L Lipton, J Desai, D Kerr, ... Clinical Cancer Research 15 (24), 7642-7651, 2009 | 475 | 2009 |
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 466 | 2022 |
| Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution SM Dewhurst, N McGranahan, RA Burrell, AJ Rowan, E Grönroos, ... Cancer discovery 4 (2), 175-185, 2014 | 428 | 2014 |
| SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation … GA Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, ... Journal of Clinical Oncology 34 (15), 1723-1731, 2016 | 402 | 2016 |
| Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised … LA Diaz, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... The Lancet Oncology 23 (5), 659-670, 2022 | 396 | 2022 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 382 | 2017 |
Jayesh DesaiPeter MacCallum Cancer Centre, University of Melbourne在 petermac.org 的电子邮件经过验证
